Alle Studien
RekrutierungPHASE3INTERVENTIONELL

A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum

This study is exploring whether a new medicine, spesolimab, can help adults with a skin condition called pyoderma gangrenosum (PG). The main goal is to see if spesolimab leads to the healing of PG ulcers. Participants will receive either spesolimab or a placebo (a dummy medicine) through a drip, along with steroid tablets initially. The study runs in two parts, with treatment assigned by chance. Doctors will regularly check participants' skin, health, and any side effects over about 1.5 years. The results will help determine if spesolimab is an effective treatment for PG.

Auf einen Blick

Status
Rekrutierung
Phase
PHASE3
Sponsor
Boehringer Ingelheim
Einschreibeziel
90
Starten
04 Feb 2025
Geschätzte Fertigstellung
19 Aug 2028

Worum geht es in dieser Studie?

You might be reading this because you or someone you know has pyoderma gangrenosum (PG), a difficult skin condition. This study is looking into a new medicine called spesolimab. The main idea is to find out if spesolimab can help heal the ulcers (open sores) that are a common problem with PG. If it works, it could offer a new way to treat this condition.

The study involves adults who have ulcerative PG, meaning they have ulcers on their skin. The ulcers need to be a certain size to join the study. Researchers want to compare spesolimab with a placebo, which looks like the real medicine but doesn't contain any active ingredients. This helps them truly understand if the medicine itself is making a difference.

By taking part, you would be helping doctors and scientists learn more about PG and how to treat it. Every participant's experience provides valuable information, bringing us closer to better treatments for everyone with this condition.

Wichtige Erkenntnisse

  • This study tests if spesolimab helps heal pyoderma gangrenosum (PG) ulcers.
  • It involves adults with specific types of PG ulcers.
  • You might receive spesolimab or a placebo, plus steroid tablets initially.
  • Treatment is given as a drip every four weeks.
  • The study lasts about 1.5 years with regular clinic visits.
  • Your participation helps to advance PG treatment research.

Wer könnte berechtigt sein?

To be able to join this study, you need to be an adult, aged 18 or over. You must also have a clear diagnosis of ulcerative pyoderma gangrenosum (PG), which means you have ulcers on your skin related to this condition. These ulcers need to be a certain size, not too small and not too large (between 5 and 80 square centimetres).

Your PG ulcer should also have been diagnosed within the last six months, though some older, active ulcers might be considered. It's important that your ulcers are not infected when you start the study. Also, if you are a woman who could become pregnant, you'll need to agree to use effective birth control throughout the study.

You cannot join if you have other types of skin sores that are not PG, or if your PG ulcers are very large. Also, if your ulcers are chronic and don't respond to usual treatments that calm the immune system, you might not be suitable for this particular study.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. Sind Sie 18 Jahre alt oder älter?
  2. Have you been diagnosed with ulcerative pyoderma gangrenosum (PG)?
  3. Do you have at least one PG ulcer between 5 and 80 square centimetres in size?
  4. Is your PG ulcer not currently infected?
  5. If you are a woman, are you willing to use effective birth control during the study?
  6. Do you not have other types of skin sores that are not PG?
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you decide to join this study, it will last for about 1.5 years. During this time, you'll visit the study clinic 20 times. At these visits, doctors will carefully check your skin – especially your PG ulcers – to see how they are healing. They will also keep a close eye on your general health and write down any side effects you might experience.

In the study, you'll receive either the medicine spesolimab or a placebo (a dummy medicine) through a drip into your arm. This drip will be given every four weeks. For the first eight weeks, all participants will also take steroid tablets by mouth. The study involves two parts, and the treatment you receive will be decided by chance, meaning it's random.

If you have open ulcers, during the second part of the study, you will receive spesolimab. If your ulcers have healed, you might get either spesolimab or the placebo. You can also withdraw from the study at any time.

Potenzielle Risiken und Vorteile

Taking part in a study like this might offer some potential benefits, such as receiving a new, experimental treatment that could help improve your pyoderma gangrenosum, access to specialist medical care, and contributing to medical science. However, there are also potential risks, as spesolimab is an investigational drug, and its full range of side effects might not be known yet. You will be closely monitored for any unwanted effects. It's important to remember that you can stop participating in the study at any time, for any reason, without it affecting your usual medical care.

Standorte (96)

  • Universität von Alabama in Birmingham
    Verifizierte Postleitzahl
    Birmingham, Vereinigte Staaten· Rekrutierung
  • Medical Dermatology Specialists Phoenix
    Verifizierte Postleitzahl
    Phoenix, Vereinigte Staaten· Rekrutierung
  • Universität von Kalifornien Irvine
    Verifizierte Postleitzahl
    Irvine, Vereinigte Staaten· Rekrutierung
  • Universität von Miami
    Verifizierte Postleitzahl
    Miami, Vereinigte Staaten· Rekrutierung
  • University of South Florida
    Verifizierte Postleitzahl
    Tampa, Vereinigte Staaten· Rekrutierung
  • Ada West Research
    Verifizierte Postleitzahl
    Meridian, United States· Noch nicht rekrutiert
  • Dawes Fretzin Clinical Research Group, LLC-Indianapolis -68995
    Verifizierte Postleitzahl
    Indianapolis, Vereinigte Staaten· Rekrutierung
  • Brigham und Frauen Krankenhaus
    Verifizierte Postleitzahl
    Boston, Vereinigte Staaten· Rekrutierung
  • Universität von Michigan
    Verifizierte Postleitzahl
    Ann Arbor, Vereinigte Staaten· Rekrutierung
  • Dartmouth Hitchcock Clinics Heater Road
    Verifizierte Postleitzahl
    Lebanon, United States· Rekrutierung
  • Dermatology at Lake Success
    Verifizierte Postleitzahl
    Lake Success, Vereinigte Staaten· Rekrutierung
  • Icahn School of Medicine am Mount Sinai
    Verifizierte Postleitzahl
    New York, Vereinigte Staaten· Rekrutierung

Häufige Fragen

What is pyoderma gangrenosum (PG)?

Pyoderma gangrenosum is a rare skin condition that causes painful sores or ulcers, especially on the legs. It's not an infection but is thought to be an autoimmune problem.

Was ist ein Placebo?

A placebo is a substance that looks exactly like the real medicine but contains no active ingredients. It helps researchers compare the effects of the actual drug against no treatment.

Why do some people get a placebo?

Giving some participants a placebo helps doctors understand if the new medicine is truly working or if improvements are due to other factors. This makes the study results more reliable.

Wie lange werde ich an der Studie teilnehmen?

You will be in this study for approximately 1.5 years (about 18 months).

Can I stop participating in the study at any time?

Yes, you have the right to withdraw from the study at any point, for any reason, without it affecting your medical care.

Wie Sie mehr erfahren können

Boehringer Ingelheim

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Interessiert daran, teilzunehmen?

Registrieren Sie Ihr Interesse

Teilen Sie Ihre Details und das Forschungsteam für "A Study to Test Whether Spesolimab Helps People With a Skin … wird Sie kontaktieren, wenn Sie möglicherweise infrage kommen. Sprechen Sie immer mit Ihrem Hausarzt, bevor Sie zustimmen, teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.